Shares of DaVita HealthCare Partners (DVA) plummeted by 12.67% on October 30, 2024, after the dialysis services provider reported mixed third-quarter results and warned of mounting cost pressures and policy uncertainties weighing on its outlook.
While DaVita's revenue of $3.26 billion surpassed analysts' expectations, driven by higher average reimbursement rates, the company's adjusted earnings per share (EPS) of $2.59 missed the consensus estimate of $2.73. The earnings miss was primarily attributed to elevated patient care costs resulting from labor cost pressures and higher medical benefits expenses.
Moreover, DaVita's treatment volumes continued to be pressured by elevated patient mortality rates, declining 0.1% year-over-year in the quarter. This ongoing challenge, coupled with the expected $10 million to $20 million impact from hurricane-related supply chain disruptions in the fourth quarter, further clouded the company's near-term outlook.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.